Background: Atrial fibrillation is a frequent co-morbidity in patients with chronic heart failure (HF) which contributes to worse outcomes. The CHAMPION trial demonstrated a significant reduction in the rate of HF hospitalizations in patients with pulmonary artery pressure monitor guided treatment. We postulated that patients with a history of atrial fibrillation (hAF) would exhibit worse baseline co-morbidities when compared to the normal sinus group, and hAF patients with physician access to remote pulmonary artery pressure data would have a significant reduction in the rate of HF hospitalizations.
